Pharmaceutical and biotechnology company AstraZeneca is partnering with Massachusetts General Hospital in order to launch two pilots of its platform AMAZE. Through this platform, the companies will work to utilize AstraZeneca's technological innovation and Mass General's clinical practices.
The goal of this platform and partnership is to improve patient outcomes and experiences by managing heart failure and asthma. AMAZE consists of a patient app and a clinician dashboard. The platform utilizes algorithms to detect issues in the patient’s care such as the need for a change in prescription.
Through the use of artificial intelligence, AMAZE also looks to cut down on costs. Data and analytics allow for increased care quality and better communication between patients and their clinicians. AMAZE looks to prioritize patients as the health industry continues to digitalize.
The platform’s pilot launch will demonstrate AMAZE’s capabilities in real world settings and AstraZeneca and Mass General will observe clinical outcomes and team communication in order to further development.
Chief Strategy Officer and Senior Managing Director of the MGH Center for Innovation in Digital HealthCare, Sara Silacci said, “At the end of the day, we both want to solve the same problems in chronic illness management - to make sure the right solution gets to the right patient at the right time in order to improve care.”
Many other digital health tools are currently being developed, such as Propeller Health’s monitoring inhalers and Biofourmis and Navartis’s deterioration detecting platform. AstraZeneca and MGH are standing out in the space by developing one app to manage many chronic illnesses.
AMAZE is currently working to manage heart failure and asthma but intends to cover a wide range of chronic illnesses in the future. At-risk patients will receive individualized care as the platform informs healthcare providers of possible adjustments and gives them the tools to work quickly and decisively. With this tool, AstraZeneca and MGH hope to set a new standard for chronic disease management and to set an example for future collaborations between technological and pharmaceutical companies, and health systems.